Mass spectrometry-based proteomics and peptidomics for biomarker discovery in neurodegenerative diseases

International Journal of Clinical and Experimental Pathology

Volumn 2, Issue 2, 2009, Pages 132-148

  Wei, Xin ^a   Li, Lingjun ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Biomarker; Mass spectrometry; Neurodegenerative diseases; Peptidomics; Post translational modifications; Proteomics

Indexed keywords

EID: 67149085949     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, Oates JA, Peck CC, Schooley RT and Spilker BA. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
2. Wagner JA, Williams SA and Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new rugs. Clin Pharmacol Ther 2007;81:104-107.
3. Davidsson P and Sjogren M. The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis Markers 2005;21:81-92.
4. Fountoulakis M and Kossida S. Proteomics-driven progress in neurodegeneration research. Electrophoresis 2006;27:1556-1573.
5. Andrade EC, Krueger DD and Nairn AC. Recent advances in neuroproteomics. Curr Opin Mol Ther 2007;9:270-281.
6. Schulenborg T, Schmidt O, van Hall A, Meyer HE, Hamacher M and Marcus K. Proteomics in neurodegeneration - disease driven approaches - Review. J Neural Transm 2006;113:1055-1073.
7. Drabik A, Bierczynska-Krzysik A, Bodzon-Kulakowska A, Suder P, Kotlinska J and Silberring J. Proteomics in neurosciences. Mass Spectrom Rev 2007;26:432-450.
8. Aebersold R and Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207.
9. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, Hochstrasser DF and Sanchez JC. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003;3: 1486-1494.
10. Pan S, Wang Y, Quinn JF, Peskind ER, Waichunas D, Wimberger JT, Jin JH, Li JG, Zhu D, Pan C and Zhang J. Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach. J Proteome Res 2006;5:2769-2779.
11. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K and Zabetian C. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 2006;9:293-348.
12. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K and Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Mol Brain Res 2003;118:140-146.
13. Castano EM, Roher AE, Esh CL, Kokjohn TA and Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 2006; 28:155-163.
14. Pan S, Rush J, Peskind ER, Galasko D, Chung K, Quinn J, Jankovic J, Leverenz JB, Zabetian C and Pan C. Application of Targeted Quantitative Proteomics Analysis in Human Cerebrospinal Fluid Using a Liquid Chromatography Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Tandem Mass Spectrometer (LC MALDI TOF/TOF) Platform. J Proteome Res 2008;7:720-730.
15. Finehout EJ, Franck Z, Choe LH, Relkin N and Lee KH. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 2007;61:120-129.
16. Yuan X and Desiderio DM. Proteomics analysis of human cerebrospinal fluid. J Chromatogr B 2005;815:179-189.
17. Carrette O, Burkhard PR, Hughes S, Hochstrasser DF and Sanchez JC. Truncated cystatin C in cerebrospiral fluid: Technical artefact or biological process? Proteomics 2005;5:3060-3065.
18. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, Vitek MP, Hovanesian V and Stopa EG. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 2007; 28:977-986.
19. Jacobs JM, Adkins JN, Qian WJ, Liu T, Shen YF, Camp DG and Smith RD. Utilizing human blood plasma for proteomic biomarker discovery. J Proteome Res 2005;4:1073-1085.
20. Hu S, Loo JA and Wong DT. Human body fluid proteome analysis. Proteomics 2006;6:6326-6353.
21. Echan LA, Tang HY, Ali-Khan N, Lee K and Speicher DW. Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomics 2005;5:3292-3303.
22. Lei Huang Harvie G, Feitelson JS, Gramatikoff K, Herold DA, Allen DL, Amunngama R, Hagler RA, Pisano MR, Zhang WW and Fang XM. Immunoaffinity separation of plasma proteins by IgY microbeads: Meeting the needs of proteomic sample preparation and analysis. Proteomics 2005;5:3314-3328.
23. Fountoulakis M, Hardmeier R, Hoger H and Lubec G. Postmortem changes in the level of brain proteins. Exp Neurol 2001;167:86-94.
24. Pierson J, Norris JL, Aerni HR, Svenningsson P, Caprioli RM and Andren PE. Molecular Profiling of Experimental Parkinson's Disease: Direct Analysis of Peptides and Proteins on Brain Tissue Sections by MALDI Mass Spectrometry. J Proteome Res 2004;3:289-295.
25. Lubec G, Krapfenbauer K and Fountoulakis M. Proteomics in brain research: potentials and limitations. Prog Neurobiol 2003;69:193-211.
26. Wolters DA, Washburn MP and Yates JR. An automated multidimensional protein identification technology for shotgun proteomics. Anal Chem 2001;73:5683-5690.
27. Delahunty CM and Yates JR. MudPIT: multidimensional protein identification technology. Biotechniques 2007;43:563, 565, 567.
28. Graham RLJ, Sharma MK, Ternan NG, Weatherly DB, Tarleton RL and McMullan G. A semi-quantitative GeLC-MS analysis of temporal proteome expression in the emerging nosocomial pathogen Ochrobactrum anthropi. Genome Biol 2007; 8:R110.
29. Wolff S, Otto A, Albrecht D, Zeng JS, Buttner K, Gluckmann M, Hecker M and Becher R. Gel-free and gel-based proteomics in Bacillus subtilis - A comparative study. Mol Cell Proteomics 2006;5:1183-1192.
30. Ficarro SB, McCleland ML, Stukenberg PT, Burke DJ, Ross MM, Shabanowitz J, Hunt DF and White FM. Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae. Nat Biotech 2002; 20:301-305.
31. Xiong L, Andrews D and Regnier F. Comparative proteomics of glycoproteins based on lectin selection and isotope coding. J Proteome Res 2003;2:618-625.
32. Zougman A, Pilch B, Podtelejnikov A, Kiehntopf M, Schnabel C, Kumar C and Mann M. Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res 2008;7:386-399.
33. Fournier ML, Gilmore JM, Martin-Brown SA and Washburn MP. Multidimensional separations-based shotgun proteomics. Chem Rev 2007;107:3654-3686.
34. Stasyk T and Huber LA. Zooming in: Fractionation strategies in proteomics. Proteomics 2004;4:3704-3716.
35. Roe MR and Griffin TJ. Gel-free mass spectrometry-based high throughput proteomics: Tools for studying biological response of proteins and proteomes. Proteomics 2006;6:4678-4687.
36. Shores KS and Knapp DR. Assessment approach for evaluating high abundance protein depletion methods for cerebrospinal fluid (CSF) proteomic analysis. J Proteome Res 2007;6:3739-3751.
37. Björhall K, Miliotis T and Davidsson P. Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 2005; 5:307-317.
38. Fenn JB, Mann M, Meng CK, Wong SF and Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989;246:64-71.
39. Karas M and Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem 1988; 60:2299-2301.
40. Domon B and Aebersold R. Mass spectrometry and protein analysis. Science 2006;312:212-217.
41. Zubarev RA, Kelleher NL and McLafferty FW. Electron capture dissociation of multiply charged protein cations. A nonergodic process. J Amer Chem Soc 1998;120:3265-3266.
42. Syka JEP, Coon JJ, Schroeder MJ, Shabanowitz J and Hunt DF. Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proc Natl Acad Sci USA 2004;101:9528-9533.
43. Ong S-E, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A and Mann M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002;1:376-386.
44. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH and Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotech 1999;17:994-999.
45. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A and Pappin DJ. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004;3:1154-1169.
46. Bondarenko PV, Chelius D and Shaler TA. Identification and relative quantitation of protein mixtures by enzymatic digestion followed by capillary reversed-phase liquid chromatography-tandem mass spectrometry. Anal Chem 2002;74:4741-4749.
47. Liu H, Sadygov RG and Yates JR. A Model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004;76:4193-4201.
48. Eng JK, McCormack AL and Yates JR. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Amer Soc Mass Spectrom 1994;5:976-989.
49. Perkins DN, Pappin DJ, Creasy DM and Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999;20:3551-3567.
50. Geer LY, Markey SP, Kowalak JA, Wagner L, Xu M, Maynard DM, Yang X, Shi W and Bryant SH. Open mass spectrometry search algorithm. J Proteome Res 2004;3:958-964.
51. Craig R and Beavis RC. TANDEM: matching proteins with tandem mass spectra. Bioinformatics 2004;20:1466-1467.
52. Clauser KR, Baker P and Burlingame AL. Role of accurate mass measurement (+/-10 ppm) in protein identification strategies employing MS or MS/MS and database searching. Anal Chem 1999;71:2871-2882.
53. Creasy DM and Cottrell JS. Unimod: Protein modifications for mass spectrometry. Proteomics 2004;4:1534-1536.
54. Lehmann WD, Bohne A andvon Der Lieth CW. The information encrypted in accurate peptide masses - improved protein identification and assistance in glycopeptide identification and characterization. J Mass Spectrom 2000;35: 1335-1341.
55. Wilkins MR, Gasteiger E, Gooley AA, Herbert BR, Molloy MP, Binz P-A, Ou K, Sanchez J-C, Bairoch A, Williams KL and Hochstrasser DF. High-throughput mass spectrometric discovery of protein post-translational modifications. J Mol Biol 1999;289:645-657.
56. Savitski MM, Nielsen ML and Zubarev RA. ModifiComb, a new proteomic tool for mapping substoichiometric post-translational modifications, finding novel types of modifications, and fingerprinting complex protein mixtures. Mol Cell Proteomics 2006;5: 935-948.
57. Kim S, Na S, Sim JW, Park H, Jeong J, Kim H, Seo Y, Seo J, Lee KJ and Paek E. MODi: a powerful and convenient web server for identifying multiple post-translational peptide modifications from tandem mass spectra. Nucleic Acids Res 2006;34:W258-W263.
58. Qian WJ, Liu T, Monroe ME, Strittmatter EF, Jacobs JM, Kangas LJ, Petritis K, Campli DG and Smith RD. Probability-based evaluation of peptide and protein identifications from tandem mass spectrometry and SEQUEST analysis: The human proteome. J Proteome Res 2005;4:53-62.
59. Wagner M, Naik D, Pothen A, Kasukurti S, Devineni R, Adam B-L, Semmes OJ and Wright G. Computational protein biomarker prediction: a case study for prostate cancer. BMC Bioinformatics 2004;5:26.
60. Li J, Zhang Z, Rosenzweig J, Wang YY and Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-1304.
61. LaBaer J. So, you want to look for biomarkers (introduction to the special biomarkers issue). J Proteome Res 2005;4:1053-1059.
62. Decramer S, Wittke S, Mischak H, Zurbig P, Walden M, Bouissou F, Bascands J-L and Schanstra JP. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med 2006;12:398-400.
63. Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, Galasko D, Pratico D, Griffin S, Schenk D and Siemers E. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Dis 2006;20:6-15.
64. Rifai N, Gillette MA and Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotech 2006;24:971-983.
65. Anderson L and Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5:573-588.
66. Stark M, Danielsson O, Griffiths WJ, Jornvall H and Johansson J. Peptide repertoire of human cerebrospinal fluid: novel proteolytic fragments of neuroendocrine proteins. J Chromatogr B 2001;754:357-367.
67. Yuan X and Desiderio DM. Human cerebrospinal fluid peptidomics. J Mass Spectrom 2005;40:176-181.
68. Geho DH, Liotta LA, Petricoin EF, Zhao W and Araujo RP. The amplified peptidome: the new treasure chest of candidate biomarkers. Curr Opin Chem Biol 2006;10:50-55.
69. Lopez MF, Mikulskis A, Kuzdzal S, Bennett DA, Kelly J, Golenko E, DiCesare J, Denoyer E, Patton WF and Ediger R. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem 2005;51:1946-1954.
70. McDonnell LA and Heeren RMA. Imaging mass spectrometry. Mass Spectrom Rev 2007;26:606-643.
71. Stoeckli M, Staab D, Staufenbiel M, Wiederhold K-H and Signor L. Molecular imaging of amyloid [beta] peptides in mouse brain sections using mass spectrometry. Anal Biochem 2002;311:33-39.
72. DeKeyser SS, Kutz-Naber KK, Schmidt JJ, Barrett-Wilt GA and Li L. Imaging mass spectrometry of neuropeptides in decapod crustacean neuronal tissues. J Proteome Res 2007;6:1782-1791.
73. Skold K, Svensson M, Nilsson A, Zhang X, Nydahl K, Caprioli RM, Svenningsson P and Andren PE. Decreased striatal levels of PEP-19 following MPTP lesion in the mouse. J Proteome Res 2006;5:262-269.
74. Jensen ON. Interpreting the protein language using proteomics. Nat Rev Mol Cell Biol 2006; 7:391-403.
75. Mann M and Jensen ON. Proteomic analysis of post-translational modifications. Nat Biotech 2003;21:255-261.
76. Kenessey A and Yen SH. The extent of phosphorylation of fetal-Tau is comparable to that ff Phf-Tau from Alzheimer paired helical filaments. Brain Res 1993;629:40-46.
77. Gunnarsson MD, Kilander L, Basun H and Lannfelt L. Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Dement Geriatr Cogn 2007;24:247-252.
78. Wang JZ, Tung YC, Wang YP, Li XT, Iqbal K and Grundke-Iqbal I. Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Lett 2001;507:81-87.
79. Vijayan S, El-Akkad E, Grundke-Iqbal I and Iqbal K. A pool of beta-tubulin is hyperphosphorylated at serine residues in Alzheimer disease brain. FEBS Lett 2001; 509:375-381.
80. Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L and Moller HJ. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Trans 2004; 111:247-272.
81. Hampel H, Buerger K, Kohnken R, Teipel SJ, Zinkowski R, Moeller HJ, Rapoport SI and Davies P. Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann Neurol 2001;49:545-546.
82. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P and Blennow K. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease - A comparative cerebrospinal fluid study. Arch Gen Psychiat 2004;61:95-102.
83. Hu YY, He SS, Wang XC, Duan QH, Grundke-Iqbal I, Iqbal K and Wang JZ. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients - An ultrasensitive bienzyme-substrate-recycle enzyme-linked Immuno-sorbent assay. Am J Pathol 2002;160:1269-1278.
84. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Andreasen N, Hofmann-Kiefer K, DeBernardis J, Kerkman D, McCulloch C, Kohnken R, Padberg F, Pirttila T, Schapiro MB, Rapoport SI, Moller HI, Davies P and Hampel H. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002;59:1267-1272.
85. Hanger DP, Betts JC, Loviny TLF, Blackstock WP and Anderton BH. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem 1998;71:2465-2476.
86. Derkinderen P, Scales TME, Hanger DP, Leung K-Y, Byers HL, Ward MA, Lenz C, Price C, Bird IN, Perera T, Kellie S, Williamson R, Noble W, Van Etten RA, Leroy K, Brion JP, Reynolds CH and Anderton BH. Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament Tau and in fetal Tau with c-Abl as the candidate tyrosine kinase. J Neurosci 2005; 25:6584-6593.
87. Reynolds CH, Betts JC, Blackstock WP, Nebreda AR and Anderton BH. Phosphorylation sites on Tau identified by nanoelectrospray mass spectrometry differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3 beta. J Neurochem 2000; 74:1587-1595.
88. Posewitz MC and Tempst P. Immobilized gallium(III) affinity chromatography of phosphopeptides. Anal Chem 1999;71:2883-2892.
89. Barnouin KN, Hart SR, Thompson AJ, Okuyama M, Waterfield M and Cramer R. Enhanced phosphopeptide isolation by Fe(III)-IMAC using 1,1,1,3,3,3-hexafluoro-isopropanol. Proteomics 2005;5:4376-4388.
90. Pinkse MWH, Mohammed S, Gouw LW, van Breukelen B, Vos HR and Heck AJR. Highly robust, automated, and sensitive on line TiO2-based phosphoproteomics applied to study endogenous phosphorylation in Drosophila melanogaster. J Proteome Res 2008;7:687-697.
91. Kweon HK and Hakansson K. Metal oxide-based enrichment combined with gas-phase ion-electron reactions for improved mass spectrometric characterization of protein phosphorylation. J Proteome Res 2008;7:749-755.
92. Trinidad JC, Specht CG, Thalhammer A, Schoepfer R and Burlingame AL. Comprehensive identification of phosphorylation sites in postsynaptic density preparations. Mol Cell Proteomics 2006;5: 914-922.
93. Collins MO, Yu L, Coba MP, Husi H, Campuzano L, Blackstock WP, Choudhary JS and Grant SGN. Proteomic analysis of in vivo phosphorylated synaptic proteins. J Biol Chem 2005;280:5972-5982.
94. Liu F, Zaidi T, Iqbal K, Grundke-Iqbal I and Gong CX. Aberrant glycosylation modulates phosphorylation of tau by protein kinase A and dephosphorylation of tau by protein phosphatase 2A and 5. Neuroscience 2002; 115:829-837.
95. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW and Gong C-X. O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease. Proc Natl Acad Sci USA 2004;101:10804-10809.
96. Saez-Valero J, Fodero LR, Sjogren M, Andreasen N, Amici S, Gallai V, Vanderstichele H, Vanmechelen E, Parnetti L, Blennow K and Small DH. Glycosylation of acetyl-cholinesterase and butyryl-cholinesterase changes as a function of the duration of Alzheimer's disease. J Neurosci Res 2003;72:520-526.
97. Yang D-S, Tandon A, Chen F, Yu G, Yu H, Arawaka S, Hasegawa H, Duthie M, Schmidt SD and Ramabhadran TV. Mature glycosylation and trafficking of nicastrin modulate its binding to presenilins. J Biol Chem 2002;277:28135-28142.
98. Charlwood J, Dingwall C, Matico R, Hussain I, Johanson K, Moore S, Powell DJ, Skehel JM, Ratcliffe S and Clarke B. Characterization of the glycosylation profiles of Alzheimer's beta - secretase protein Asp-2 expressed in a variety of cell lines. J Biol Chem 2001;276:16739-16748.
99. Botella-Lopez A, Burgaya F, Gavin R, Garcia-Ayllon MS, Gomez-Tortosa E, Pena-Casanova J, Urena JM, Del Rio JA, Blesa R, Soriano E and Saez-Valero J. Reelin expression and glycosylation patterns are altered in Alzheimer's disease. Proc Natl Acad Sci USA 2006;103:5573-5578.
100. Kaji H, Saito H, Yamauchi Y, Shinkawa T, Taoka M, Hirabayashi J, Kasai K-i, Takahashi N and Isobe T. Lectin affinity capture, isotope-coded tagging and mass spectrometry to identify N-linked glycoproteins. Nat Biotech 2003;21:667-672.
101. Cummings RD and Kornfeld S. Fractionation of asparagine-linked oligosaccharides by serial lectin-agarose affinity chromatography. A rapid, sensitive, and specific technique. J Biol Chem 1982;257:11235-11240.
102. Qiu R and Regnier FE. Use of Multidimensional lectin affinity chromatography in differential glycoproteomics. Anal Chem 2005;77:2802-2809.
103. Zhang H, Li X-j, Martin DB and Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotech 2003;21:660-666.
104. Vosseller K, Trinidad JC, Chalkley RJ, Specht CG, Thalhammer A, Lynn AJ, Snedecor JO, Guan S, Medzihradszky KF and Maltby DA. O-linked N-acetylglucosamine proteomics of postsynaptic density preparations using lectin weak affinity chromatography and mass spectrometry. Mol Cell Proteomics 2006;5: 923-934.
105. Zubarev RA. Electron-capture dissociation tandem mass spectrometry. Curr Opin Biotechnol 2004;15:12-16.
106. Mariani E, Polidori MC, Cherubini A and Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: An overview. J Chromatogr B 2005;827:65-75.
107. Giasson BI, Ischiropoulos H, Lee VMY and Trojanowski JQ. The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radical Bio Med 2002;32: 1264-1275.
108. Korolainen MA, Goldsteins G, Alafuzoff I, Koistinaho J and Pirttila T. Proteomic analysis of protein oxidation in Alzheimer's disease brain. Electrophoresis 2002;23:3428-3433.
109. Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW and Markesbery WR. Protein oxidation in the brain in Alzheimer's disease. Neuroscience 2001;103:373-383.
110. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR and Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part 1: Creatine kinase bb, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radical Bio Med 2002;33: 562-571.
111. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR and Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 2002;82: 1524-1532.
112. Soreghan BA, Yang F, Thomas SN, Hsu J and Yang AJ. High-throughput proteomic-based identification of oxidatively induced protein carbonylation in mouse brain. Pharm Res 2003;20:1713-1720.
113. Soreghan BA, Lu BW, Thomas SN, Duff K, Rakhmatulin EA, Nikolskaya T, Chen T and Yang AJ. Using proteomics and network analysis to elucidate the consequences of synaptic protein oxidation in a PS1+A beta PP mouse model of Alzheimer's disease. J Alzheimers Dis 2005;8:227-241.
114. Poon HF, Farr SA, Banks WA, Pierce WM, Klein JB, Morley JE and Butterfield DA. Proteomic identification of less oxidized brain proteins in aged senescence-accelerated mice following administration of antisense oligonucleotide directed at the A[beta] region of amyloid precursor protein. Mol Brain Res 2005;138:8-16.
115. Reynolds MR, Berry RW and Binder LI. Nitration in neurodegeneration: Deciphering the "Hows" "nYs". Biochemistry 2007;46: 7325-7336.
116. Danielson SR and Andersen JK. Oxidative and nitrative protein modifications in Parkinson's disease. Free Radical Bio Med 2008;44:1787-1794.
117. Sacksteder CA, Qian WJ, Knyushko TV, Wang H, Chin MH, Lacan G, Melega WP, Camp DG, Smith RD and Smith DJ. Endogenously nitrated proteins in mouse brain: links to neurodegenerative disease. Biochemistry 2006;45:8009-8022.
118. Zhang Q, Qian WJ, Knyushko TV, Clauss TRW, Purvine SO, Moore RJ, Sacksteder CA, Chin MH, Smith DJ and Camp DG. A method for selective enrichment and analysis of nitrotyrosine-containing peptides in complex proteome samples. J Proteome Res 2007;6: 2257-2268.
119. Wang GP, Khatoon S, Iqbal K and Grundke-Iqbal I. Brain ubiquitin is markedly elevated in Alzheimer disease. Brain Res 1991; 566:146-151.
120. Keller JN, Hanni KB and Markesbery WR. Impaired proteasome function in Alzheimer's disease. J Neurochem 2000;75:436-439.
121. Wang D and Cotter RJ. Approach for determining protein ubiquitination sites by MALDI-TOF mass spectrometry. Anal Chem 2005;77:1458-1466.
122. Kirkpatrick DS, Denison C and Gygi SP. Weighing in on ubiquitin: the expanding role of mass-spectrometry-based proteomics. Nat Cell Biol 2005;7:750-757.
123. Dorval V and Fraser PE. SUMO on the road to neurodegeneration. Biochimica et Biophysica Acta (BBA) - Mol Cell Res 2007; 1773:694-706.
124. Li T, Evdokimov E, Shen R-F, Chao C-C, Tekle E, Wang T, Stadtman ER, Yang DCH and Chock PB. Sumoylation of heterogeneous nuclear ribonucleoproteins, zinc finger proteins, and nuclear pore complex proteins: A proteomic analysis. Proc Natl Acad Sci USA 2004;101: 8551-8556.
125. Cooper HJ, Tatham MH, Jaffray E, Heath JK, Lam TT, Marshall AG and Hay RT. Fourier transform ion cyclotron resonance mass spectrometry for the analysis of small ubiquitin-like modifier (SUMO) modification: identification of lysines in RanBP2 and SUMO targeted for modification during the E3 autoSUMOylation reaction. Anal Chem 2005; 77:6310-6319.
126. Jones J, Wu K, Yang Y, Guerrero C, Nillegoda N, Pan Z-Q and Huang L. A targeted proteomic analysis of the ubiquitin-like modifier Nedd8 and associated proteins. J Proteome Res 2008;7:1274-1287.
127. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, Sayre LM, Monnier VM and Perry G. Advanced maillard reaction end-products are associated with Alzheimer-disease pathology. Proc Natl Acad Sci USA 1994;91: 5710-5714.
128. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K and Cerami A. Advanced glycation end-products contribute to amyloidosis in Alzheimer-disease. Proc Natl Acad Sci USA 1994;91:4766-4770.
129. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, Scott CW, Caputo C, Frappier T and Smith MA. Glycated Tau-protein in Alzheimer-disease - A mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994; 91:7787-7791.
130. Takeuchi M, Sato T, Takino JI, Kobayashi Y, Furuno S, Kikuchi S and Yamagishi SI. Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer's disease. Med Hypotheses 2007; 69:1358-1366.
131. Lapolla A, Fedele D, Seraglia R and Traldi P. The role of mass spectrometry in the study of non-enzymatic protein glycation in diabetes: An update. Mass Spectrom Rev 2006;25: 775-797.
132. Gadgil HS, Bondarenko PV, Treuheit MJ and Ren D. Screening and sequencing of glycated proteins by neutral loss scan LC/MS/MS method. Anal Chem 2007;79:5991-5999.